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PRisk and Fate of Cerebral Embolism
After Transfemoral Aortic Valve Implantation
A Prospective Pilot Study With
Diffusion-Weighted Magnetic Resonance Imaging
Alexander Ghanem, MD,* Andreas Müller, MD,† Claas P. Nähle, MD,† Justine Kocurek, MD,*
Nikos Werner, MD,* Christoph Hammerstingl, MD,* Hans H. Schild, MD, PHD,†
Jörg O. Schwab, MD, PHD,* Fritz Mellert, MD,§ Rolf Fimmers, MD,‡ Georg Nickenig, MD, PHD,*
Daniel Thomas, MD†
Bonn, Germany
Objectives The aim of this study was prospective investigation of silent and clinically apparent cerebral embolic events and
neurological impairment after transfemoral aortic valve implantation (TAVI).
Background TAVI is a novel therapeutic approach for multimorbid patients with severe aortic stenosis. We investigated peri-
interventional cerebral embolism with diffusion-weighted magnetic resonance imaging (DW-MRI) and its relation-
ship to clinical and serologic parameters of brain injury.
Methods Cerebral DW-MRI was performed before, directly, and 3 months after TAVI with the current third-generation self-
expanding CoreValve (Medtronic, Minneapolis, Minnesota) prosthesis. At the timepoints of the serial MRI studies,
focal neurological impairment was assessed according to the National Institutes of Health Stroke Scale (NIHSS),
and serum concentration of neuron-specific enolase (NSE), a marker of the volume of brain tissue involved in an
ischemic event, were determined.
Results Thirty patients were enrolled; 22 completed the imaging protocol. Three patients (10%) had new neurological
findings after TAVI, of whom only 1 (3.6%) had a permanent neurological impairment. Of the 22 TAVI patients
with complete imaging data, 16 (72.7%) had 75 new cerebral lesions after TAVI presumed to be embolic. The
NIHSS and NSE were not correlated with DW-MRI lesions.
Conclusions The incidence of clinically silent peri-interventional cerebral embolic lesions after TAVI is high. However, in this cohort
of 30 patients, the incidence of persistent neurological impairment was low. (Incidence and Severity of Silent and
Apparent Cerebral Embolism After Conventional and Minimal-invasive Transfemoral Aortic Valve Replacement;
NCT00883285) (J Am Coll Cardiol 2010;55:1427–32) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.026(
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firansfemoral aortic valve implantation (TAVI) is a novel
herapeutic option for multimorbid, elderly patients with
ymptomatic aortic stenosis (1). Transfemoral aortic valve
mplantation involves mechanical stress to the aorta and the
ortic valve caused by catheter manipulation, balloon dilation,
etrograde valve positioning, and frame expansion. The inci-
ence of clinically apparent cerebral ischemia related to TAVI
anges from 0.6% to 10% (1–3). Hence, there has been concern
egarding the peri-interventional risk of cerebral embolism.
rom the Departments of *Medicine/Cardiology, †Radiology, ‡Statistics and Bio-
etrics, and §Cardiothoracic Surgery, University of Bonn, Bonn, Germany. Drs.
hanem and Müller contributed equally to this work.d
Manuscript received October 8, 2009; revised manuscript received November 16,
009, accepted December 7, 2009.Cerebral diffusion-weighted magnetic resonance imaging
DW-MRI) enables detection and localization of acute isch-
mic lesions with high sensitivity and specificity. Previously,
W-MRI has been employed to evaluate the risk of cerebral
mbolism associated with cardiovascular procedures (4). Fur-
hermore, embolic lesions detected by DW-MRI have been
ssociated with clinical impairment and serologic biomarkers
f brain damage (5). More specifically, neuron-specific enolase
NSE) concentration has been found to correlate closely with
he volume of ischemic stroke (6). However, its relationship to
AVI-related cerebral embolism has not been elucidated yet.
Thus, the aim of this pilot study was to investigate the
ncidence of clinically silent and apparent cerebral embolism
n patients undergoing TAVI and to correlate DW-MRI
ndings with clinical and serologic markers of brain
amage.
i
a
o
d
M
1
B
r
n
c
d
T
s
o
m
D
b
S
m
C
c
p
W
t
w
R
T
i
p
(
P
V
f
t
1428 Ghanem et al. JACC Vol. 55, No. 14, 2010
TAVI-Related Cerebral Embolism April 6, 2010:1427–32Methods
Between November 2008 and
June 2009, all patients scheduled
for TAVI at our institution were
screened for inclusion into this
prospective study. Indication for
TAVI was in concordance with
the recent consensus statement
(7). Detailed inclusion and exclu-
sion criteria are depicted in the
Online Methods section. The
study was approved by the local
medical ethics committee, and all
patients signed informed, written
consent. Cerebral DW-MRI was
performed in patients before (E1),
within 3 days (E2), and 3 months
after (E3) TAVI (Fig. 1). At these
timepoints, focal neurological
mpairment was assessed by a certified cardiologist following
standardized protocol according to the National Institutes
f Health Stroke Scale (NIHSS), and serum NSE was
etermined (Liaison NSE, Diasorin, Italy).
Figure 1 Study Protocol
Thirty patients were eligible for the study protocol. Eight patients could not be
investigated with magnetic resonance imaging (MRI) serially due to death,
hemodynamic instability, new-onset of claustrophobia, and necessity of post-
interventional permanent pacemaker (PM) therapy. DW-MRI  diffusion-
weighted magnetic resonance imaging; E1  before transfemoral aortic valve
implantation; E2  within 3 days of transfemoral aortic valve implantation;
E3  3 months after transfemoral aortic valve implantation; NIHSS  National
Institutes of Health Stroke Scale; NSE  neuron-specific enolase; TAVI 
transfemoral aortic valve implantation.
Abbreviations
and Acronyms
DW-MRI  diffusion-weighted
magnetic resonance imaging
E1  before transfemoral
aortic valve implantation
E2  within 3 days of
transfemoral aortic valve
implantation
E3  3 months after
transfemoral aortic valve
implantation
NIHSS  National
Institutes of Health
Stroke Scale
NSE  neuron-specific
enolase
TAVI  transfemoral aortic
valve implantationdRI. Quantitative cranial DW-MRI was performed with a
.5-T whole body system (Intera, Philips Medical Systems,
est, the Netherlands). Scans were read by 2 experienced
adiologists blinded to the timing of the imaging and the
eurological status of the patient. In case of discrepancy, a
onsensus reading was held. Detailed protocols and method of
ata analysis are presented in the Online Methods section.
AVI. The third-generation (18-F) CoreValve revalving
ystem (Medtronic, Inc., Minneapolis, Minnesota) consists
f a tri-leaflet bioprosthetic porcine pericardial tissue valve
ounted and sutured in a self-expanding nitinol frame.
etails of TAVI are described in the Online data and have
een published previously (1).
tatistical analyses. Continuous variables are presented as
ean  SD. Ordinal data were analyzed by means of
ochran-Armitage test for trend. Categorical variables were
ompared by chi-square statistics or Fisher exact test. The
aired, 2-sided Student t test and the Mann-Whitney-
ilcoxon test were used for comparison. Association be-
ween frequency of embolic events and continuous variables
as examined by Spearman’s correlation.
esults
hirty patients were enrolled. Clinical and serological
nvestigations could be obtained in 28 patients (93%); 22
atients (73%) completed the entire study protocol
Table 1). 4The E2 and E3 were performed 2.2  0.4
atient CharacteristicsTable 1 Patient Characteristics
Clinical data
Age, yrs 79.3 4.8
Male 8 (36.4)
Body mass index, kg/m2 26 6.2
Log. EuroScore, % 19.4 13.5
STS score–mortality, % 6.2 4.2
STS score–permanent stroke, % 2.8 1.3
Peak-to-peak-gradient, mm Hg 50.3 22
Ejection fraction, % 53 16.6
NT-pro-BNP level, pg/ml 3,323 (948–10,220)
NYHA functional class 3 0.5
Comorbidities
Hypertension 21 (95)
Diabetes 5 (23)
Smoking 8 (36)
Dyslipidemia 20 (91)
Creatinine, mg/dl 1.5 1.2
Hemodialysis 2 (9)
CHADS2 score 3.1 1.1
Prior stroke 6 (27)
Prior TIA 3 (14)
PVD 15 (68)
Aortic atheroma 4 mm 11 (50)
alues are mean  SD, n (%), or median (interquartile range).
NT-pro-BNP  N-terminal pro-B-type natriuretic peptide; NYHA  New York Heart Association
unctional class; PVD  peripheral vascular disease; STS  Society of Thoracic Surgeons; TAVI 
ransfemoral aortic valve implantation; TIA  transient ischemic attack.ays and 91  5 days after TAVI, respectively. Two
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April 6, 2010:1427–32 TAVI-Related Cerebral Embolismatients were lost to all E2 and E3 investigations, due to
eath within 2 days after TAVI due to coronary stent
hrombosis (autopsy) and acute heart failure, respectively.
he post-interventional necessity of permanent pace-
aker implantation (n  4), new onset of claustrophobia
n  1), and hemodynamic instability impeding transport
o DW-MRI (n  1) reflect the reasons for the other 6
issing DW-MRI studies.
RI. All patients showed brain atrophy and hyperintense
hite matter lesions at E1. Eleven patients revealed lacunar
efects, and 5 showed old territorial infarcts. No patient
evealed acute ischemic lesions in the baseline DW-MRI. At
2, a total of 75 new lesions were detected (range: 0 to 19
esions/patient) in 16 patients (72.7%). Representative MRI
Figure 2 TAVI-Related Cerebral Embolism
(A) Images obtained in an 83-year-old man show 1 ischemic lesion (arrow). The patie
in a 73-year-old man demonstrates multiple, bilateral embolism of the cerebrum and c
inversion recovery sequence as sign of neuronal repair (yellow arrows). The patient h
obtained in an 84-year-old man show 1 ischemic lesion in the right cerebellum (arrow
W-MRI Lesion Localization and Size After TAVITable 2 DW-MRI Lesion Localization and Size After TAVI
Vascular Territories DW-MRI Lesion Volume Range (cm3)
Anterior cerebral artery 0.1–59.2
Middle cerebral artery 0.1–4.5
Posterior cerebral artery 0.1–8.6
Vertebro-basilary arteries 0.1–1.6nt had no clinically apparent focal neurological deficits after TAVI (NIHSS: 0). (B) A DW-MRI
erebellum (arrows). Selected emboli demonstrate signal intensity in the fluid-attenuated
ad no clinically apparent focal neurological deficits after TAVI (NIHSS: 0). (C) Images
). The patient demonstrated transient ataxia (NIHSS: 4). Abbreviations as in Figure 1.WI diffusion-weightedmagnetic resonance imaging; TAVI transfemoral aortic valve implantation.Figure 3 Vascular Distribution of Embolic Lesions
Localization of diffusion-weighted magnetic resonance imaging (DW-MRI)
lesions after transfemoral aortic valve implantation (TAVI) depicted as embolic
events in each vascular territory on a per-patient basis. ACA  anterior cere-
bral artery; L  left; MCA  middle cerebral artery; PCA  posterior cerebral
artery; R  right; VERT BAS  vertebro-basilary arteries.
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TAVI-Related Cerebral Embolism April 6, 2010:1427–32xaminations are depicted in Figure 2. Thirty-one of 75 lesions
41.3%) were demonstrated in patients with lacunar defects
nd old infarcts. Of those, 59 and 16 new ischemic lesions were
ocated in supratentoral and infratentoral regions, respectively
Table 2). Interestingly, the majority of the supratentorial
esions (67.8%) were located on the left side (Fig. 3). Three of
6 patients (18.7%) with a TAVI-related cerebral embolism
t E2 developed a focal signal increase in the region
orresponding to the original index lesion, showing in-
arcted brain tissue at E3.
To evaluate the association of calculated risks of mortality
nd permanent stroke, regression analyses of risk scores and
requency of DW-MRI lesions were performed. Post-
nterventional embolism demonstrated no significant associa-
ion with calculated mortality with EuroScore (r0.33, p
.13), Society of Thoracic Surgeons score (r  0.24,
 0.27), and Society of Thoracic Surgeons score permanent
troke (r  0.21, p  0.35).
eurological and biochemical evaluation. Patient #1 re-
orted onset of unspecific dizziness 48 h after TAVI (Table 3).
ndividual Neurological Risk and Outcome in Consecutive TAVI PatTable 3 Individual Neurological Risk and Outcome in Consecut
Patient #
Sex/Age
(yrs)
Stroke-Risk
(%)*
Procedure Time
(min)
1 M/84 3.5 47
2 M/88 4.0 87
3 F/81 6.3 71
4 M/85 2.1 90
5 F/88 2.5 129
6 F/79 2.7 70
7 M/76 1.9 90
8 F/69 1.4 60
9 F/78 6.8 92
10 F/83 3.7 96
11 M/73 1.4 103
12 F/88 4.4 103
13 F/75 2.9 51
14 M/85 1.7 127
15 M/80 5.0 142
16 F/70 2.5 95
17 F/71 3.9 72
18 F/77 2.4 60
19 M/74 1.4 115
20 M/82 2.8 90
21 F/85 2.2 67
22 F/84 2.0 80
23 F/82 4.8 81
24 M/69 1.6 105
25 F/79 1.5 195
26 F/80 2.0 112
27 F/80 2.7 162
28 M/78 3.1 85
29 M/75 1.3 73
30 F/85 5.2 116
STS score–permanent stroke; †neuron-specific enolase (NSE) at E1 (g/l)  NSE at E2 (g/l); ‡
DW-MRI  diffusion-weighted magnetic resonance imaging; E1  before transfemoral aortic valve im
ransfemoral aortic valve implantation; NIHSS  National Institutes of Health Stroke Scale; TAVI  transeurological examination revealed transient cerebellar ataxia
NIHSS: 4). Patient #15 demonstrated onset of persistent
evere focal neurological deficits 36 h after TAVI. Neurological
ssessment showed left-sided hemiparesis resulting in an NIHSS
f 16 points. Patient #16 demonstrated transient dysarthria
8 h after TAVI. Three months after TAVI neurological
xamination revealed no significant deficits in all but 1 (Patient
15) of the surviving 28 patients (3.6%). The NSE did not
ncrease significantly after TAVI (19.1 13.5 g/l [E1], 22.6
7.3 g/l [E2], 14.5  4.5 g/l [E3]; p  NS).
otential sources of embolism. To elucidate potential sources
f cerebral embolism, baseline characteristics of patients with and
ithout embolic lesions in DW-MRI were compared (Table 4).
e observed a slightly higher prevalence of cerebrovascular and
eripheral artery disease and aortic atheroma in patients with
mbolic lesions in DW-MRI. Interestingly, all patients with
rame dilation (n 4) had embolic events. Procedural duration
f TAVI was not significantly higher in patients with embolic
vents. Correlation of duration time and number of embolic
vents was not significant (r  0.12, p  0.59).
VI Patients
W-MRI Lesion (E2)
Total Volume (cm3)
NIHSS
Delta NSE†E1 E2 E3
5/4.7 0 4 0  0.6
Not performed‡ 0 0 0  2.0
6/2.0 0 0 0  16.7
Not performed§ 0 0 — § — §
1/0.1 0 0 0  31.0
1/0.1 0 0 0  0.1
Not performed 0 0 0  14.6
Not performed¶ 0 0 0  15.0
Not performed‡ 0 0 0  10.7
3/1.0 0 0 0  3.7
19/4.9 0 0 0  69.9
Not performed§ 0 0 — §  21.7
1/0.1 0 0 0  1.8
1/1.3 0 0 0  25.1
6/70.3 0 16 16  9.4
17/7.8 0 1 0  2.3
0/0 0 0 0  13.0
2/0.3 0 0 0  6.4
4/0.4 0 0 0  0.3
2/0.3 0 0 0  7.4
0/0 0 0 0  1.3
0/0 0 0 0  13.7
2/0.4 0 0 0  15.8
Not performed‡ 0 0 0  8.7
4/0.6 0 0 0  11.7
0/0 0 0 0  1.8
0/0 0 0 0  12.0
0/0 0 0 0  1.6
1/0.3 0 0 0  2.4
Not performed‡ 0 0 0  4.1
ker-therapy; §death; claustrophobia; ¶hemodynamic Instability.ientsive TA
D
n/
pacema
plantation; E2  within 3 days of transfemoral aortic valve implantation; E3  3 months after
femoral aortic valve implantation.
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April 6, 2010:1427–32 TAVI-Related Cerebral Embolismiscussion
ecent studies reported on clinically apparent stroke rates
anging from 0.6% to 10% after TAVI (2,3). In this study
e prospectively assessed the frequency of clinically silent
nd apparent cerebral embolism with DW-MRI in mul-
imorbid patients undergoing TAVI. Our main finding is
hat TAVI is associated with a high rate of clinically
ilent cerebral embolism (72.7%). In contrast, clinical
ymptoms of neurological deficits persisted in only 3.6%
Patient Characteristics Related to DW-MRI ResTable 4 Patient Characteristics Related to
DW-MRI Lesi
(n 
Clinical data
Age, yrs 79.7
Male 1 (17
Body mass index, kg/m2 26.1
EuroScore, % 19.0
STS score–mortality, % 6.5
STS score–permanent stroke, % 2.7
NYHA functional class 3
Comorbidities
Hypertension 5 (83
Diabetes 1 (17
Smoking 1 (17
Dyslipidemia 5 (83
Creatinine, mg/dl 2.5
Hemodialysis 2 (33
Prior stroke 1 (17
Prior TIA 0 (0)
Peripheral vascular disease 2 (33
Cerebral vascular disease 1 (17
Aortic atheroma 4 mm 2 (33
Atrial fibrillation 2 (33
Atrial flutter 1 (17
CHADS2 score 2.8
Coronary artery disease
Coronary artery disease 4 (67
Prior myocardial infarction 3 (50
Prior PCI 1 (17
Prior CABG 0 (0)
Procedural data
Procedure time, min 96.3
CoreValve 26/29-mm diameter 3/3
Additional frame dilation 0 (0)
Medication (E1)
Acetylsalicylic acid 6 (10
Clopidogrel hydrogen sulphate 6 (10
Beta-blocker 6 (10
Statin 5 (83
AT1 antagonist 1 (17
ACE inhibitor 2 (33
Diuretics 5 (83
Values are mean  SD, n (%), or n. *Statistical analysis not feasible.
ACE angiotensin-converting enzyme; CABG coronary artery bypa
PCI  percutaneous coronary intervention; other abbreviations as in Tf the investigated patients 3 months after TAVI. aAt this time, it remains speculative as to which of the
ollowing procedural steps is responsible for embolic events:
assage of the aortic valve, balloon dilation, retrograde valve
ositioning, or frame expansion. All were conducted in
equence for ethical reasons. The passage of a stenotic aortic
alve with the catheter resulted in an incidence of cerebro-
ascular embolic lesions as high as 22% (4). The prepon-
erance of left-sided DW-MRI lesions in this study might
e the result of flow characteristics and warrants further
nvestigation. The investigation of patients undergoing
RI Results
sent DW-MRI Lesions Present
(n  16) p Value
79.2 4.9 0.84
7 (44) 0.26
25.9 5.7 0.95
19.6 15 0.62
6.1 4.7 0.81
2.9 1.5 0.64
3 0.5 1.0
16 (100) 0.27
4 (25) 1.0
7 (44) 0.35
15 (94) 0.48
1.2 0.3 0.019
0 (0) 0.065
5 (31) 0.63
3 (19) 0.53
13 (81) 0.054
7 (44) 0.35
9 (56) 0.63
7 (44) 1.0
1 (6) 0.48
3.2 1.2 0.5
11 (69) 1.0
8 (50) 1.0
8 (50) 0.35
0 (0) —*
96.6 38.5 0.99
11/5 0.75
4 (25) 0.46
16 (100) —*
16 (100) —*
14 (88) 1.0
13 (81) 1.0
2 (13) 1.0
7 (44) 1.0
11 (69) 0.63
t surgery; DW-MRI diffusion-weighted magnetic resonance imaging;ultsDW-M
ons Ab
6)
5
)
8
9.2
2.6
0.8
0.6
)
)
)
)
2.1
)
)
)
)
)
)
)
0.8
)
)
)
35.8
0)
0)
0)
)
)
)
)ntegrade transapical AVI with DW-MRI could help
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TAVI-Related Cerebral Embolism April 6, 2010:1427–32lucidate the influence of retrograde passage of the aortic
rch and valve as potential embolic sources.
Three months after TAVI, neurological deficits persisted
n only 3.6%. The presence of transient symptoms in 2
urther patients did not correlate with ischemic lesions
evealed by DW-MRI. Absence of apparent symptoms on
he one hand can be explained with location of embolic
vents in noneloquent brain areas. On the other hand,
IHSS does not detect nonfocal neurological impairment
e.g., memory dysfunction or neurocognitive decline at 3
onths) (8). However, the knowledge about silent TAVI-
elated cerebral embolism could raise awareness for the
areful management of peri-interventional anticoagulation.
tudy limitations. The limited number of patients im-
edes a multivariate statistical analysis identifying indepen-
ent risk factors for TAVI-related embolism. The incidence
f silent and apparent cerebral embolism might differ with
he Edwards-SAPIEN prosthesis (Edwards Lifesciences
nc., Irvine, California). Whether patients with similar
eri-interventional risk undergoing operative aortic valve
eplacement would have comparable neurological outcome
emains speculative (5).
onclusions
he incidence of clinically silent peri-interventional cerebral
mbolic lesions after TAVI is high, whereas the incidence of
ersistent neurological impairment in elderly patients with
ultiple high-risk comorbid conditions was low.
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